Raloxifene in clinical practice. Results of non-interventional study CORAL (COmpliance with RALoxifene)

Česká verzia

Authors: J. Rosa ¹; P. Vaňuga ²; J. Payer ³; A. Svobodník ⁴
Authors place of work: DC MEDISCAN - Euromedic/Osteocentrum Praha, vedoucí MUDr. Petr Kasalický, CSc. ¹; Národný endokrinologický a diabetologický ústav Ľubochňa, Slovenská republika, riaditeľ doc. MUDr. Jozef Michálek, CSc. ²; V. interná klinika Lekárskej fakulty UK a FNsP Bratislava, Slovenská republika, prednosta prof. MUDr. Juraj Payer, CSc. ³; Institut biostatistiky a analýz MU Brno, ředitel doc. RNDr. Ladislav Dušek, Dr. ⁴
Published in the journal: Vnitř Lék 2008; 54(3): 217-224
Category: Original Contributions

Summary

Osteoporosis is a disease causing higher bone fragility and bone ruptures occurring even in minimal traumas. Good patient compliance is the prerequisite for long-term efficacy of osteoporosis treatment. Compliance data from randomised clinical studies may not provide reliable information about compliance in clinical practice which is usually lower. CORAL (COmpliance with RALoxifene therapy) is a local, Slovak, non-interventional, open, prospective, uncontrolled and multicentre study of woman patients on raloxifen therapy in current clinical practice. Raloxifen is a selective estrogen receptor modulator (SERM) indicated for the treatment and prevention of postmenopausal osteoporosis.

Objectives:
The primary objective of the study was to assess compliance with raloxifen therapy in the conditions of current clinical practice. The secondary objectives were the assessment of the impact of therapy on the quality of life, of treatment satisfaction and treatment safety.

Patients and methods:
A total of 1497 patients with proven postmenopausal osteoporosis were enrolled in the 18-month study performed in 40 centres. Compliance was evaluated on the basis of the number of omissions in the use of the evaluated drug. Treatment satisfaction was evaluated by the patients who used a 0–100 visual analogue scale (VAS). Quality of life was evaluated by means of an EQ-5D quality of life questionnaire. In order to measure treatment safety, all adverse events were recorded by the supervising physician in a dedicated questionnaire at every visit.

Statistical methods used:
The non-parametrical Mann-Whitney test was used to assess the relation between raloxifen treatment compliance and the selected parametres (quality of life, treatment satisfaction, changes in health condition, premature discontinuation of therapy). The maximum likelihood ratio χ2 test and Fisher’s exact test (for 2 × 2 tables) were used to analyse the ratio between compliance and reasons for enrolment in the study. Changes in treatment satisfaction in the course of the study were analysed using the Wilcoxon test. All the used tests were bilateral and data was assessed at a 5 % level of significance.

Results:
The mean age of the patients enrolled in the study was 63.4 ± 8.0 years. 58 % of patients were enrolled on the basis of densitometric evidence of osteoporosis, 74 % of patients were enrolled for proven osteoporosis which had been manifested by a fracture, and osteoporotic fracture as such was the reason to start therapy in 10 % of patients. The majority of patients enrolled in the study (77 %) had natural menopause. The mean period from menopause to the study was 15 years. Acceptable cooperation (≥ 80 % of medication used) was recorded for more than 90 % of patients during the study, and total dosing adherence was recorded more than 58 % of patients. A significantly higher satisfaction with pharmacotherapy was observed in the patients who adhered to the prescribed dosing schedule. Adherence to the prescribed dosing schedule was also associated with a considerable better health condition and a higher quality of life. In a total of 1,497 evaluated patients, treatment was prematurely discontinued in 87 (5.8 %) women. The attending physician’s decision, adverse events or the patient’s request were relatively evenly distributed among the reasons for the discontinuation of therapy. Premature discontinuation of therapy was mostly recorded in patients who were not satisfied with the pharmacotherapy of osteoporosis as such, in women who were less satisfied with their overall health condition and who had a lower quality of life.

Discussion:
The study showed very good patient compliance with raloxifen. The above findings associate with a significant correlation between the degree of adherence to therapy, treatment satisfaction and the overall health condition and quality of life. Premature discontinuation of therapy was observed in a very low number of women. It can be concluded that raloxifen therapy provides effective treatment of osteoporosis based on long-term cooperation of patients.

Conclusion:
Effective treatment of postmenopausal osteoporosis with raloxifen is related to excellent cooperation of patients on a long-term basis.

Keywords:
raloxifene – osteoporosis – compliance – non-interventional study

Zdroje

1. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. WHO Technical Series Report 843, World Health Organisation, Geneva, 1994.

2. Štěpán J, Havelka S, Kamberská Z et al. Epidemiologie der Osteoporose in der Tschechischen Republik. J Miner Stoffwechs 2002; 9: 7-13.

3. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285: 785-795.

4. Melton LJ 3rd, Chrischilles EA, Cooper C et al. Perspective. How many women have osteoporosis? J Bone Miner Res 1992; 7: 1005-1010.

5. Rosa J. Raloxifen - lékový profil. Remedia 2007; 17: 430-436.

6. Lufkin EG, Wong M, Deal C. The role of selective estrogen receptor modulators in the prevention and treatment of postmenopausal osteoporosis. Rheum Dis Clin North Am 2001; 27: 163-185.

7. Delmas PD, Genant HK, Crans CC. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 2003; 33: 522-532.

8. Cauley JA, Norton L, Lippman ME et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treatment 2001; 65: 125-134.

9. Martino S, Cauley JA, Barrett-Connor E et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004; 96: 1751-1761.

10. Baker VL, Ulrich U, Taylor RN. Estrogen replacement and alternatives for the prevention and treatment of osteoporosis. Curr Probl Obstet Gynecol Fertil 1999; 22: 77-119.

11. Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 1997; 102: 43-49.

12. Fawcett J. Compliance: definitions and key issues. J Clin Psychiatry 1995; 56(Suppl 1): 4-8.

13. Melnikow J, Kiefe C. Patient compliance and medical research: issues in methodology. J Gen Intern Med 1994; 9: 96-105.

14. Delmas PD, Bjarnason NH, Mitlak BH et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337: 1641-1647.

15. Ettinger B, Black DM, Mitlak BH et al (for the MORE study group). Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 1999; 282: 637-645.

16. Walsh BW, Kuller LH, Wild RA et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998; 279: 1445-1451.

17. Davies GS, Huster WJ, Shen W et al. Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women. Menopause 1999; 6: 188-195.

18. Cummnings SR, Eckert S, Krueger KA et al (for the MORE study group). The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 1999; 281: 2189-2197.

19. Davies GC, Huster WJ, Lu Y et al. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol 1999; 93: 558-565.

20. Silverman SL, Minshall ME, Shen W et al. The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis. Results from the MORE study. Arthr Rheum 2001; 44: 2611-2619.

21. Houpt LS, Minshall ME, Shen W et al. Study completer analysis of quality of life results from a clinical trial of a selective estrogen receptor modulator, raloxifene, and hormone replacement therapy. Calcified Tissue Int 1997; 61: S503.

22. Voss S, Hunter MS, Bäckström T et al. Comparison of raloxifene and contiunous combined HRT - effects of compliance on quality of life. Osteoporosis Int 2000; 11(Suppl 5): S5.

23. Haynes RB, Sackett DL, Gibson ES et al. Improvement of medication compliance in uncontrolled hypertension. Lancet 1976; 1: 1265-1268.

24. Yood RA, Srinivas Emani S, Reed JI et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 2003; 14: 965-968.

25. Turbi C, Herrero-Beaumont G, Acebes JC et al. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin Ther 2004; 26: 245-256.

26. Lips P, van Schoor NM. Quality of life in patients with osteoporosis. Osteoporos Int 2005; 16: 447-455.

27. Caro JJ, Ishak KJ, Huybrechts KF et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004; 15: 1003-1008.